These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Bauriedel G; Skowasch D; Schneider M; Andrié R; Jabs A; Lüderitz B Am Heart J; 2003 Feb; 145(2):343-8. PubMed ID: 12595854 [TBL] [Abstract][Full Text] [Related]
4. [20 years of cardiovascular epidemiology. The clinician's viewpoint]. Bertrand ME Rev Epidemiol Sante Publique; 1996 Nov; 44(6):556-62. PubMed ID: 9005491 [TBL] [Abstract][Full Text] [Related]
5. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Cohen M Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347 [TBL] [Abstract][Full Text] [Related]
6. Optimal medical management of peripheral arterial disease. Rice TW; Lumsden AB Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725 [TBL] [Abstract][Full Text] [Related]
7. North American perspective of antiplatelet agents. Gorelick PB Adv Neurol; 2003; 92():281-91. PubMed ID: 12760195 [No Abstract] [Full Text] [Related]
9. Effect of an ongoing educational program on the use of antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs in patients with coronary artery disease seen in an academic cardiology clinic. Nayak D; Aronow WS Cardiol Rev; 2005; 13(2):95-7. PubMed ID: 15705260 [TBL] [Abstract][Full Text] [Related]
10. Individualized approach to the management of coronary heart disease: identifying the nonresponders before it is too late. Ganz P; Hsue PY J Am Coll Cardiol; 2009 Jan; 53(4):331-3. PubMed ID: 19161881 [No Abstract] [Full Text] [Related]
12. [Drug therapy of coronary heart disease--are therapeutic guidelines being paid attention to?]. Böger GI; Hoopmann M; Busse R; Budinger M; Welte T; Böger RH Z Kardiol; 2003 Jun; 92(6):466-75. PubMed ID: 12819995 [TBL] [Abstract][Full Text] [Related]
13. [Secondary prevention of coronary heart disease. How effective are modern therapy methods?]. Kolenda KD Dtsch Med Wochenschr; 2003 Sep; 128(36):1849-53. PubMed ID: 12964107 [No Abstract] [Full Text] [Related]
14. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP; Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929 [TBL] [Abstract][Full Text] [Related]
15. Use of evidence-based management for acute coronary syndrome. Tang E; Wong CK; Wilkins G; Herbison P; Williams M; Kay P; Restieaux N N Z Med J; 2005 Oct; 118(1223):U1678. PubMed ID: 16224502 [TBL] [Abstract][Full Text] [Related]
16. Can the ESPRIT results end the antiplatelet battle between neurologists and cardiologists? Albers GW Nat Clin Pract Cardiovasc Med; 2007 Mar; 4(3):118-9. PubMed ID: 17330124 [No Abstract] [Full Text] [Related]
18. [Platelet inhibitors from a cardiological viewpoint: evidence based therapy and new concepts for the acute coronary syndrome without ST-segment elevation]. Ivandic BT; Giannitsis E Hamostaseologie; 2006 May; 26(2):119-22. PubMed ID: 16676054 [TBL] [Abstract][Full Text] [Related]
19. President's page: the promise of prevention: so, why aren't all cardiologists "preventive"? Wolk MJ; Bairey Merz CN; Thompson PD J Am Coll Cardiol; 2004 Nov; 44(10):2082-4. PubMed ID: 15542296 [No Abstract] [Full Text] [Related]
20. Antiplatelet drug resistance: not ready for prime time. Burns TL; Mooss AN; Hilleman DE Pharmacotherapy; 2005 Nov; 25(11):1621-8. PubMed ID: 16232023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]